RedHawk Holdings Corp (OTC: SNDD), a diversified holding company primarily engaged in sales and distribution of medical devices, has received an order to provide an expedited delivery for 2,000 of its digital non-contact thermometers to the City of New York, it was reported on Monday.
The company aims to complete delivery before the end of April.
Presently, the company offers for sale the SANDD mini and the SANDD Pro, an FDA approved digital non-contact thermometer, KN95 masks, and is to soon offer for sale a surgical mask.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial